{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:55Z","timestamp":1792892095453,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.118018","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:46:39Z","timestamp":1777563999000},"page":"118018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Amelioration of the pharmacokinetics and tissue distribution of flurbiprofen axetil by glycyrrhetinic acid derivatives for enhanced safety and efficacy"],"prefix":"10.1016","volume":"250","author":[{"given":"Xiaojing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaosong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhai","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118018_b0005","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2174\/138161205774414510","article-title":"Why drugs fail\u2013a study on side effects in new chemical entities","volume":"11","author":"Schuster","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2026.118018_b0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118018_b0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41467-025-55945-4","article-title":"Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose","volume":"16","author":"Aldawod","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118018_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.104146","article-title":"Design and synthesis of carbamate-linked ester prodrugs selectively activated by carboxylesterase 1 with enhanced stability against intestinal hydrolysis","volume":"115","author":"Takahashi","year":"2026","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2026.118018_b0025","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1248\/bpb.19.1178","article-title":"Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats","volume":"19","author":"Ogiso","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2026.118018_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aea2989","article-title":"Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers","volume":"12","author":"Cheng","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118018_b0035","article-title":"Prodrug-based drug delivery systems: strategic approaches and emerging challenges in targeted therapeutics","author":"Chaturvedi","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0040","article-title":"Prodrug-inspired adenosine triphosphate-activatable celastrol-Fe(III) chelate for cancer therapy","volume":"10","author":"Li","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118018_b0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/acscentsci.5c00576","article-title":"Carbamate prodrugs restrict in vivo metabolism and improve the pharmacokinetics of isoniazid","volume":"11","author":"Sankar","year":"2025","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bcp.2026.118018_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17425255.2024.2348491","article-title":"Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review","volume":"20","author":"Liu","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2026.118018_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116128","article-title":"Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology","volume":"223","author":"Nagaoka","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/dmd.121.000649","article-title":"Transcriptional regulation of carboxylesterase 1 in Human Liver: role of the nuclear receptor subfamily 1 group H member 3 and its splice isoforms","volume":"50","author":"Collins","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118018_b0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41401-024-01407-4","article-title":"Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice","volume":"46","author":"Wang","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118018_b0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/dmd.121.000476","article-title":"Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation","volume":"49","author":"Parvez","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118018_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv132","article-title":"Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma","volume":"107","author":"Capello","year":"2015","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2026.118018_b0080","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","article-title":"Carboxylesterase in the liver and small intestine of experimental animals and human","volume":"81","author":"Taketani","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118018_b0085","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/dmd.108.024331","article-title":"Different inhibitory effects in rat and human carboxylesterases","volume":"37","author":"Takahashi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118018_b0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/dmd.30.5.541","article-title":"Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression","volume":"30","author":"Xie","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118018_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109566","article-title":"Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism","volume":"345","author":"Song","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2026.118018_b0100","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2174\/0929867325666171204155558","article-title":"Carboxylesterase inhibitors: an update","volume":"25","author":"Zou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118018_b0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2026.118018_b0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00498258709043936","article-title":"Extrapolation from animals to man: predictions, pitfalls and perspectives","volume":"17","author":"Ruelius","year":"1987","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2026.118018_b0115","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1016\/j.apsb.2025.08.007","article-title":"Discovery of orally active and serine-targeting covalent inhibitors against hCES2A for ameliorating irinotecan-triggered gut toxicity","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118018_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115742","article-title":"Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis","volume":"215","author":"Cao","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143967","article-title":"Discovery of cardiovascular drugs as effective inhibitors of human carboxylesterase","volume":"311","author":"Lv","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118018_b0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejmech.2016.02.020","article-title":"Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2","volume":"112","author":"Zou","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118018_b0135","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-003-0574-6","article-title":"Differences in flurbiprofen pharmacokinetics between CYP2C9*1\/*1, *1\/*2, and *1\/*3 genotypes","volume":"58","author":"Lee","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0140","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1248\/bpb.26.1448","article-title":"4\u2019-hydroxylation of flurbiprofen by rat liver microsomes in fasting and feeding conditions","volume":"26","author":"Shimizu","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2026.118018_b0145","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/jphp.12443","article-title":"Cyclosporin A-sensitive cytotoxicity of flurbiprofen non-stereoselectively mediated by cytochrome P450 metabolism in three-dimensional cultured rat hepatocytes","volume":"67","author":"Tanino","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0002-9343(86)90134-8","article-title":"European experience with flurbiprofen. A new analgesic\/anti-inflammatory agent","volume":"80","author":"Buchanan","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2026.118018_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007358.pub2","article-title":"Single dose oral flurbiprofen for acute postoperative pain in adults","author":"Sultan","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcp.2026.118018_b0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cmdc.201300490","article-title":"Targeted fluorination of a nonsteroidal anti-inflammatory drug to prolong metabolic half-life","volume":"9","author":"Shaughnessy","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2026.118018_b0165","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1590\/1807-3107bor-2024.vol38.0108","article-title":"Comparison of the analgesic efficacy of spray and tablet flurbiprofen for pain after soft tissue surgery","volume":"38","author":"Eroglu","year":"2024","journal-title":"Braz. Oral Res."},{"key":"10.1016\/j.bcp.2026.118018_b0170","unstructured":"L. Dean, Flurbiprofen Therapy and CYP2C9 Genotype, in: V.M. Pratt, S.A. Scott, M. Pirmohamed, B. Esquivel, B.L. Kattman, A.J. Malheiro (Eds.), Medical Genetics Summaries, National Center for Biotechnology Information (US), Bethesda (MD), 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537365\/ (accessed March 4, 2026)."},{"key":"10.1016\/j.bcp.2026.118018_b0175","first-page":"683","article-title":"NSAID-induced gastric ulceration is dose related by weight: an endoscopic study with flurbiprofen","volume":"88","author":"Lanza","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bcp.2026.118018_b0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs","volume":"104","author":"Cryer","year":"1998","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2026.118018_b0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/019262338801600217","article-title":"The propionic acids. Gastrointestinal toxicity in various species","volume":"16","author":"Elliott","year":"1988","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.bcp.2026.118018_b0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14728214.10.4.687","article-title":"The unexpected side effects of new nonsteroidal anti-inflammatory drugs","volume":"10","author":"Uzan","year":"2005","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2026.118018_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.gastro.2008.05.030","article-title":"Gastric mucosal defense and cytoprotection: bench to bedside","volume":"135","author":"Laine","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2026.118018_b0200","article-title":"In-depth summary of adverse events associated with Flurbiprofen: a real-world pharmacovigilance study from 2004 to 2024 using the FAERS database","volume":"20","author":"Yang","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118018_b0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/chir.23531","article-title":"Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil","volume":"35","author":"He","year":"2023","journal-title":"Chirality"},{"key":"10.1016\/j.bcp.2026.118018_b0210","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.2147\/DDDT.S542722","article-title":"Exploring the population pharmacokinetic and pharmacogenetics characteristics of Flurbiprofen isomers in selective joint replacement patients with postoperative pain","volume":"19","author":"Yao","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2026.118018_b0215","doi-asserted-by":"crossref","first-page":"995","DOI":"10.12659\/MSM.890102","article-title":"Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bcp.2026.118018_b0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13318-014-0248-z","article-title":"A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid","volume":"41","author":"Ogata","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118018_b0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jchromb.2015.04.037","article-title":"Liquid chromatography-tandem mass spectrometry for the quantification of flurbiprofen in human plasma and its application in a study of bioequivalence","volume":"993\u2013994","author":"Mei","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bcp.2026.118018_b0230","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2147\/JPR.S176475","article-title":"Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Pain Res."},{"key":"10.1016\/j.bcp.2026.118018_b0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2026.118018_b0240","doi-asserted-by":"crossref","first-page":"888","DOI":"10.31083\/ph.2011.1549","article-title":"Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs","volume":"66","author":"Liu","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.bcp.2026.118018_b0245","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1039\/D3RA08025K","article-title":"A review of typical biological activities of glycyrrhetinic acid and its derivatives","volume":"14","author":"Chen","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bcp.2026.118018_b0250","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6699560","article-title":"Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and glycyrrhetinic acids","volume":"2021","author":"Richard","year":"2021","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2026.118018_b0255","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.2174\/1389557522666220126093033","article-title":"A review on structure-activity relationships of glycyrrhetinic acid derivatives with diverse bioactivities","volume":"22","author":"Liu","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118018_b0260","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fphar.2017.00435","article-title":"Structure-activity relationships of pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1","volume":"8","author":"Zou","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70259","article-title":"Design, synthesis, in vitro and in vivo biological evaluation of novel Pyrazolo[3,4-d]pyrimidine-based derivatives as promising multitarget candidates for Alzheimer\u2019s disease","volume":"87","author":"Nemr","year":"2026","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2026.118018_b0270","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00204-017-1946-5","article-title":"Phenyl valerate esterase activity of human butyrylcholinesterase","volume":"91","author":"Mangas","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2026.118018_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105143","article-title":"Strain and sex differences in drug hydrolase activities in rodent livers","volume":"142","author":"Kisui","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2026.118018_b0280","first-page":"1189","article-title":"Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2","volume":"60","author":"Humerickhouse","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118018_b0285","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118018_b0290","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1248\/bpb.b24-00645","article-title":"Functional analysis of modified Caco-2 cells carrying CES2A1 as a model for intestinal absorption of prodrugs","volume":"48","author":"Imai","year":"2025","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2026.118018_b0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ympev.2010.05.018","article-title":"Genomic analysis of the carboxylesterases: identification and classification of novel forms","volume":"57","author":"Williams","year":"2010","journal-title":"Mol. Phylogenet. Evol."},{"key":"10.1016\/j.bcp.2026.118018_b0300","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1124\/dmd.111.041335","article-title":"Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human","volume":"39","author":"Williams","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118018_b0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","article-title":"The mammalian carboxylesterases: from molecules to functions","volume":"38","author":"Satoh","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2026.118018_b0310","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s11095-023-03590-1","article-title":"Elucidation of carboxylesterase mediated pharmacokinetic interactions between irinotecan and oroxylin a in rats via physiologically based pharmacokinetic modeling","volume":"40","author":"Zhang","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2026.118018_b0315","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1023\/A:1007661209921","article-title":"A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling","volume":"17","author":"Ploeger","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2026.118018_b0320","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","article-title":"Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn\u2019t the stomach digest itself?","volume":"88","author":"Wallace","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2026.118018_b0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1476-5381.2011.01509.x","article-title":"NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies","volume":"165","author":"Wallace","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118018_b0330","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/gut.35.9.1197","article-title":"Mucosal adaptation to aspirin induced gastric damage in humans, studies on blood flow, gastric mucosal growth, and neutrophil activation","volume":"35","author":"Konturek","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2026.118018_b0335","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1590\/S0004-28032016000100008","article-title":"Administration of H2 blockers in Nsaid induced Gastropathy in rats: effect on histopathological changes in gastric, hepatic and renal tissues","volume":"53","author":"Manocha","year":"2016","journal-title":"Arq. Gastroenterol."},{"key":"10.1016\/j.bcp.2026.118018_b0340","first-page":"71","article-title":"Morphological changes in the structure, regional blood circulation and content of the prostaglandins in the rats intestinal mucosa at different NSAIDS effects","author":"Tkachenko","year":"2010","journal-title":"Eksp Klin Gastroenterol"},{"key":"10.1016\/j.bcp.2026.118018_b0345","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1124\/molpharm.121.000357","article-title":"Construction and characterization of CRISPR\/Cas9 knockout rat model of carboxylesterase 2a Gene","volume":"100","author":"Liu","year":"2021","journal-title":"Mol. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:39:06Z","timestamp":1792888746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":69,"alternative-id":["S0006295226003515"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118018","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.177366304.43880019\/v1","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amelioration of the pharmacokinetics and tissue distribution of flurbiprofen axetil by glycyrrhetinic acid derivatives for enhanced safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118018"}}